A phase 3 clinical trial found ultra-high dose methylcobalamin slowed functional decline in patients with early-stage ALS

A phase 3 clinical trial found ultra-high dose methylcobalamin slowed functional decline in patients with early-stage amyotrophic lateral sclerosis. ja.ma/3L1hd6C

Question

Does twice-weekly intramuscular injection of 50-mg ultrahigh-dose methylcobalamin slow clinical progression in early-stage amyotrophic lateral sclerosis?

Findings

In this randomized phase 3 clinical trial that included 130 participants who were enrolled within 1 year from symptom onset and presented with a 1- or 2-point decrease on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale total score during 12 weeks of observation, the changes in the score were −2.66 with methylcobalamin vs −4.63 with placebo during the 16-week treatment, which significantly differed.

Meaning

Ultrahigh-dose methylcobalamin may slow functional decline in early-stage amyotrophic lateral sclerosis with moderate progression rate.

jamanetwork.com/journals/ja...

twitter.com/JAMANeuro/statu...

twitter.com/ScienceofPD/sta...

twitter.com/ScienceofPD/sta...

[Hidden]

Thank you for sharing this. Would you mind sharing your method of finding the great info you share? Do you frequently check JAMA Neurology? Subscribe to specific sites? Thank you, Novice Newbie Neuro Researcher 😊

[Hidden in reply to Hidden]

Mostly twitter.👍👍👍

[Hidden in reply to Hidden]

Thank you.